Defence Therapeutics Hires Dr. Amie Phinney as Strategy & Business Advisor to Guide Growth

Defence Therapeutics has engaged Dr. Amie Phinney as a Strategy & Business Advisor to guide its next phase of growth. Dr. Phinney has over 20 years of experience in life sciences commercialization, directing alliances, leading strategic planning, and business operations across global R&D. She will work closely with senior leadership to refine and align the company's short- and long-term strategies as it pursues new directions emerging from recent scientific advances.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Dr. Amie Phinney, PhD, MBA, as its new Strategy & Business Advisor. Dr. Phinney brings over 20 years of experience in life sciences commercialization, directing alliances, leading strategic planning, and business operations across global R&D. She will work closely with senior leadership to refine and align the company's short- and long-term strategies as it pursues new directions emerging from recent scientific advances [1].

Dr. Phinney's extensive background includes roles at Abbott and AbbVie Pharmaceuticals, where she directed alliances and led strategic planning and business operations. She also served as Chief Scientific Officer at Lakeside Discovery and Senior Director of Partnerships and Business Development at adMare BioInnovations. Her entrepreneurial experience includes co-founding Block Biosciences Inc. and Discovery-2-Innovation Life Sciences Consulting, where she guided numerous biotech start-ups and academic groups in both the USA and Canada [1].

The appointment comes at a pivotal point for Defence Therapeutics, which specializes in drug delivery technologies and is developing the next generation of ADC products using its proprietary platform, ACCUM®. This technology enables precision delivery of ADCs in their intact form to target cells, potentially increasing efficacy and potency against cancer [1].

The collaboration between Defence Therapeutics and Dr. Phinney follows a trend of strategic partnerships in the life sciences sector aimed at driving innovation and efficiency. For instance, IQVIA and Flagship Pioneering have formed a strategic collaboration to accelerate life sciences innovation, leveraging IQVIA's comprehensive capabilities in information assets, analytics, and domain expertise across the drug development life cycle [2].

Meanwhile, Alibaba Group has been upgrading its valuation potential with a $165 price target, citing AI/cloud investments and e-commerce stabilization. The company's $380 billion AI/cloud investment has driven significant revenue growth and is a key growth engine for the long-term [3].

Dr. Phinney's appointment signals Defence Therapeutics' commitment to strategic growth and innovation, aligning with broader industry trends. The company's forward-looking statements highlight the potential for significant advancements in antibody-delivered therapeutics, positioning Defence Therapeutics for sustainable growth [1].

References:
[1] https://www.newsfilecorp.com/release/264605
[2] https://www.ainvest.com/news/iqvia-flagship-pioneering-collaborate-accelerate-life-sciences-innovation-2508/
[3] https://www.ainvest.com/news/alibaba-group-valuation-potential-post-bernstein-upgrade-strategic-catalysts-long-term-growth-drivers-stabilizing-commerce-ecosystem-2509/